AC-0676 (AC-0676) - 药物靶点：BTK x BTK C481S_在研适应症：B …
This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: * Identify the recommended dose of AC676 …
AC676 was designed as a chimeric degrader to link BTK to the cereblon E3-ligase, thereby inducing subsequent ubiquitination and degradation of BTK. AC676 degrades BTK protein …
A Phase 1 Study of AC676, a Novel BTK Chimeric Degrader, in …
2024年11月5日 · AC676-001 is a Phase 1 dose-escalation study of AC676 administered orally once daily as monotherapy in patients with relapsed and refractory B-cell malignancies. …
Design and optimization strategies of PROTACs and its Application ...
2025年1月1日 · Hong-Yi Zhao et al has mentioned small molecule PROTACs targeting EGFR generated by integrating a reversible EGFR-TKI with a purine scaffold and a CRBN or VHL …
Accutar Biotech
2023年2月3日 · AC0676 is an orally bioavailable, chimeric degrader molecule designed to target and degrade Bruton’s Tyrosine Kinase (BTK) with high potency, selectivity, and broad mutant …
Next-generation cancer therapeutics: PROTACs and the role of ...
2025年1月5日 · CRBN-based PROTAC 97a demonstrated antiproliferative activity (IC 50 = 11.69 μM), lipid peroxide buildup (two-fold increase in response to DMSO), and GPX4 breakdown …
冰洲石生物宣布，FDA批准AC0676用于B细胞恶性肿瘤I期试验的IN…
美国食品药品管理局 (FDA)已批准该公司在研新药AC0676用于治疗复发/难治性B细胞恶性肿瘤患者的试验用新药申请 (IND) 专注于利用人工智能 (AI)赋能药物发现的生物技术公司冰洲石生物 …
Abstract CT156: A Phase I study evaluating AC676, an innovative …
2024年4月5日 · AC676 was designed as a chimeric degrader to target and degrade BTK using Accutar's proprietary Protein-Protein Interaction Targeting Chimeras (PPI-TAC) platform. By …
Trial | NCT05780034
This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: * Identify the recommended dose of AC676 …
AC676 / Accutar Biotech - LARVOL
AC0676 is an orally bioavailable, chimeric degrader molecule designed to target and degrade Bruton's Tyrosine Kinase (BTK) with high potency, selectivity, and broad mutant …